1.
Baseline patient clinical characteristics
| Characteristics | n (%) |
| FISH, fl uorescence in situ hybridization. | |
| Age [median, (range)] (year, N=90) | 51 (31-73) |
| ≥median | 47 (55.22) |
| <median | 43 (47.78) |
| Hormone-receptor status (N=90) | |
| ER+ and/or PgR+ | 54 (60.00) |
| ER-/PgR- | 34 (37.78) |
| Unknown | 2 (2.22) |
| HER-2 receptor status (N=90, primary or metastasis site) | |
| HER-2+ (by IHC or FISH) | 85 (94.44) |
| Unknown | 5 (5.56) |
| Number of lymph node metastasis after surgery | |
| (N=81) | |
| 0 | 30 (37.04) |
| 1-3 | 19 (23.46) |
| 4-9 | 17 (20.99) |
| ≥10 | 12 (14.81) |
| Unknown | 3 (3.70) |
| Histological grade: Scarff-Bloom-Richardson | |
| (N=90) | |
| 1 | 6 (6.67) |
| 2 | 50 (55.56) |
| 3 | 21 (23.33) |
| Unknown | 13 (14.44) |
| Metastatic sites before trastuzumab initiation | |
| (N=90) | |
| Bone and soft tissue | 83 (92.22) |
| Thoracic and abdominal cavity | 13 (14.44) |
| Lung | 29 (32.22) |
| Brain | 6 (6.67) |
| Liver | 56 (62.22) |
| Neoadjuvant or adjuvant chemotherapy regimen | |
| (N=90) | |
| Anthracyclines±paclitaxels | 65 (72.22) |
| Anthracyclines±paclitaxels+trastuzumab | 9 (10.00) |
| Others | 3 (3.33) |
| None | 13 (14.44) |
| Numbers of metastatic site before trastuzumab | |
| (N=90) | |
| 1 | 32 (35.56) |
| 2 | 26 (28.89) |
| ≥3 | 32 (35.56) |
| ER, estrogen receptor; PgR, progesterone receptor; IHC, immunohistochemistry; | |